Determination of olverembatinib in human plasma and cerebrospinal fluid by an LC-MS/MS method: Validation and clinical application

Xiang, Dong; Zhao, Tianzhi; Wang, Jue; Cao, Yang; Yu, Qiuxia; Liu, Lu; Yu, Hongjuan; Li, Xiping; Li, Ninghong; Yang, Yi; Gong, Xun

doi:10.1016/j.jpba.2023.115382

Cited by 2 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the National Comprehensive Cancer Network (NCCN) guidelines for Ph + -ALL, CNS prophylaxis remains part of the standard care regardless of BCR/ABL1 TKI application. A study in vitro revealed that olverembatinib may have a potent ability to penetrate into the CNS, which strongly suggests the prophylactic role in CNS-L ( Xiang et al, 2023 ). Thus, it may be possible to spare preventive intrathecal injections for CNS-L in clinical settings of third-generation BCR/ABL1 TKI.…”

Section: Discussionmentioning

confidence: 99%

Case report: Olverembatinib monotherapy: the chemotherapy-free regimen for an elderly patient with relapsed Ph-positive acute lymphoblastic leukemia

Ding,

2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: The advent of first- and second-generation BCR/ABL1 tyrosine kinase inhibitors (TKIs), such as imatinib and dasatinib, has markedly improved the clinical outcomes of patients with philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+-ALL). However, due to acquired drug resistance, most Ph+-ALL patients experience relapse. Thus, third-generation BCR/ABL1 TKIs, including ponatinib and olverembatinib, have been developed with the aim of overcoming drug resistance.Case report: A 79-year-old woman presented with intermittent fever and fatigue for 4 days. After comprehensive cytogenetic examination, the patient was diagnosed with Ph+-B-ALL. Starting on 22 September 2021, a combined regimen of flumatinib and vincristine/prednisone (VP) was administered for seven cycles, followed by flumatinib maintenance therapy. The patient remained in first complete molecular remission (1st CMR) for 19 months. On 12 March 2023, she again complained of fatigue and loss of appetite for nearly a month. A comprehensive examination showed Ph+-B-ALL relapse with additional E255V mutation, although T315I mutation was negative. In view of her frail physical condition, she received olverembatinib monotherapy and achieved second CMR (second CMR). No severe toxicities were recorded except for mild fatigue. At present, she has been in second CMR for over 6 months.Conclusion: For elderly patients with relapsed Ph+-ALL, olverembatinib monotherapy may offer a novel option with a good safety profile, suggesting the feasibility of a chemo-free regimen.

show abstract

Section: Discussionmentioning

confidence: 99%